Safinamide is a selective monoamine oxidase B (MAO-B) inhibitor used as an adjunct to levodopa/carbidopa in the treatment of mid- to late-stage idiopathic Parkinson’s disease. It prolongs the "ON-time" of levodopa by inhibiting the degradation of dopamine and also modulates glutamate release through blockade of voltage-dependent sodium channels, providing both dopaminergic and non-dopaminergic mechanisms of action. It is indicated to extend the therapeutic effect of levodopa without increasing dyskinesia.